Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

NCT04504370 on ClinicalTrials.gov · last registry update 2023-07-28

Finished 30 March 2022, after enrolling 273 people. Primary outcome, as filed: Change in HbA1c. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: PegBio Co., Ltd.
Sponsor type: Other
Enrollment: 273
Started: 2020-04-27
Primary completion: 2022-03-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.